JSC Grindeks announces it has received the statement of the company’s Member of the Board Sergejs Batalins on his resignation from the position of Member of the Board starting from 12th of October, 2015.
In the Board of JSC Grindeks in accordance with the resolution of the Supervisory Council of JSC Grindeks has been elected Ibraim Muhtsi who was the Chairman of the Board of a subsidiary of JSC Grindeks – JSC “Tallinn Pharmaceutical Plant” – until now. Previously, Muhtsi had also worked at JSC Grindeks as the Director of Sales. In his career, Muhtsi has also worked as a medical practitioner, as well as he has run the department of Anaesthesiology and Intensive Care at Viru Central Hospital (Estonia).
By taking up his duties as a Member of the Board of JSC Grindeks Ibraim Muhtsi will also become a Commercial director of the company and will be responsible for the Group’s marketing and sales functions.
Muhtsi has graduated from the University of Tartu, Estonia obtaining a Doctor’s diploma in Anaesthesia and Intensive Care specialty.
Ibraim Muhtsi does not own shares of JSC Grindeks.
The Members of the Board, Chairman of the Board Juris Bundulis and Chief Finance and Administrative Officer Vadims Rabsha continue their work in the Board of JSC «Grindeks».